A phase II study of pembrolizumab in patients with malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery

Update Il y a 4 ans
Reference: EUCTR2015-004747-39

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Main Objective: To evaluate the percentage of patients with curatively unresectable MPNST who have achieved clinical response; complete response (CR), partial response (PR), or stable disease (SD) at 18 weeks as assessed by the Investigator, by using RECIST, v1.1.


Inclusion criteria

  • Malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery

Links